Charles Schwab Investment Management Inc. boosted its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 4.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 400,006 shares of the medical instruments supplier’s stock after acquiring an additional 15,549 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.54% of West Pharmaceutical Services worth $187,607,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in WST. Invesco Ltd. grew its stake in West Pharmaceutical Services by 14.0% in the 3rd quarter. Invesco Ltd. now owns 1,260,099 shares of the medical instruments supplier’s stock valued at $534,963,000 after acquiring an additional 154,534 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in West Pharmaceutical Services by 42.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 515,148 shares of the medical instruments supplier’s stock valued at $218,701,000 after purchasing an additional 153,180 shares in the last quarter. Brown Advisory Inc. lifted its holdings in West Pharmaceutical Services by 8.5% in the 4th quarter. Brown Advisory Inc. now owns 1,338,591 shares of the medical instruments supplier’s stock valued at $627,811,000 after purchasing an additional 105,397 shares in the last quarter. Marshall Wace LLP lifted its holdings in West Pharmaceutical Services by 60.4% in the 3rd quarter. Marshall Wace LLP now owns 249,099 shares of the medical instruments supplier’s stock valued at $105,753,000 after purchasing an additional 93,783 shares in the last quarter. Finally, TD Asset Management Inc. lifted its holdings in West Pharmaceutical Services by 45.7% in the 4th quarter. TD Asset Management Inc. now owns 293,227 shares of the medical instruments supplier’s stock valued at $137,526,000 after purchasing an additional 91,923 shares in the last quarter. 93.25% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have weighed in on WST. William Blair restated an “outperform” rating on shares of West Pharmaceutical Services in a report on Tuesday, February 22nd. StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Thursday, April 28th.
NYSE WST opened at $300.68 on Friday. West Pharmaceutical Services, Inc. has a 52 week low of $288.12 and a 52 week high of $475.35. The company has a quick ratio of 2.18, a current ratio of 2.89 and a debt-to-equity ratio of 0.09. The business’s fifty day simple moving average is $363.05 and its 200-day simple moving average is $394.16. The firm has a market cap of $22.27 billion, a PE ratio of 33.41, a P/E/G ratio of 3.11 and a beta of 1.17.
West Pharmaceutical Services (NYSE:WST – Get Rating) last posted its quarterly earnings results on Thursday, April 28th. The medical instruments supplier reported $2.30 EPS for the quarter, topping the consensus estimate of $2.18 by $0.12. West Pharmaceutical Services had a return on equity of 30.33% and a net margin of 23.76%. The business had revenue of $720.00 million for the quarter, compared to analyst estimates of $720.92 million. During the same quarter in the previous year, the firm earned $2.05 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Research analysts expect that West Pharmaceutical Services, Inc. will post 9.34 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 3rd. Stockholders of record on Wednesday, July 20th will be issued a dividend of $0.18 per share. The ex-dividend date of this dividend is Tuesday, July 19th. This represents a $0.72 annualized dividend and a dividend yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio is presently 8.00%.
About West Pharmaceutical Services (Get Rating)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.